United States Military Cancer Institute-based trials demonstrated that lymph node-positive (LN +) or LN- breast cancer patients who received an optimal dose of the E75 vaccine experienced similar safety issues to those vaccinated with suboptimal doses; however, exhibited superior HER-2/neu-endorsed immunity to lessen the chance of breast tumor recurrence [200]. This evidence concerns the gene ERBB2 and breast carcinoma.